NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

頭頸椎癌症治療藥的全球市場:各診斷方法、治療類型、疾病適應症、給藥途徑、治療等級、終端用戶、地區,競爭預測和機會(2026年)

Global Head and Neck Cancer Therapeutics Market By Diagnostic Methods, By Treatment Type, By Disease Indication, By Route of Administration, By Therapeutic Class, By End User, By Region, Competition Forecast & Opportunities, 2026

出版商 TechSci Research 商品編碼 1008713
出版日期 內容資訊 英文 115 Pages
商品交期: 請詢問到貨日
價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

頭頸椎癌症治療藥的全球市場:各診斷方法、治療類型、疾病適應症、給藥途徑、治療等級、終端用戶、地區,競爭預測和機會(2026年) Global Head and Neck Cancer Therapeutics Market By Diagnostic Methods, By Treatment Type, By Disease Indication, By Route of Administration, By Therapeutic Class, By End User, By Region, Competition Forecast & Opportunities, 2026
出版日期: 2021年06月01日內容資訊: 英文 115 Pages
簡介

全球頭頸椎癌症治療藥市場,由於全球患者數增加,在預測期間內預計以7.71%大幅度的年複合成長率成長,達到29億3,426萬美元。

由於政府和各種民間組織的癌症啟發計劃,導致國民的意識高漲和早期的癌症診斷,成為該市場的主要成長要素。再加上對癌症更脆弱的高齡人口增加,也成為該市場的主要的成長要素。

隨著醫療服務的提高和有益的醫療改革,全球各地頭頸椎癌症治療藥的需求劇增。再加上為了開發理想的治療方法的廣泛的研究開發活動,預期促進今後數年的市場成長。

本報告提供全球頭頸椎癌症治療藥市場的相關調查,市場規模和預測,佔有率,COVID-19的影響,成長要素和課題,各診斷方法、治療類型、疾病適應症、給藥途徑、治療等級、終端用戶、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 產品概要

第2章 調查手法

第3章 COVID-19對全球頭頸椎癌症治療藥市場的影響

第4章 摘要整理

第5章 客戶的迴響

  • 品牌認知度和品牌追憶
  • 購買決策的影響因素
  • 未滿足需求與課題

第6章 全球頭頸椎癌症治療藥市場預測

  • 市場規模與預測
    • 各銷售額
  • 市場佔有率與預測
    • 各診斷方法(切片檢查,影像診斷,內視鏡檢驗,其他)
    • 各治療類型(手術,放射線治療,化療,免疫療法,標靶治療)
    • 各疾病適應症(嘴唇及口腔癌症,喉癌症,中咽癌症,唾液腺癌症,鼻咽癌症,下嚥癌症)
    • 各給藥途徑(注射劑,口服劑)
    • 各治療等級(PD抑制劑,EGFR抑制劑,微管抑制劑)
    • 各終端用戶(醫院,專門診所,門診病人手術中心,其他)
    • 各企業(2020)
    • 各地區
  • 產品市場地圖

第7章 北美的頭頸椎癌症治療藥市場預測

  • 市場規模與預測
    • 各銷售額
  • 市場佔有率與預測
    • 各診斷方法
    • 各治療類型
    • 各疾病適應症
    • 各給藥途徑
    • 各治療等級
    • 各終端用戶
    • 各國
  • 北美:各國分析
    • 美國
    • 加拿大
    • 墨西哥

第8章 歐洲的頭頸椎癌症治療藥市場預測

  • 市場規模與預測
    • 各銷售額
  • 市場佔有率與預測
    • 各診斷方法
    • 各治療類型
    • 各疾病適應症
    • 各給藥途徑
    • 各治療等級
    • 各終端用戶
    • 各國
  • 歐洲:各國分析
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利

第9章 亞太地區頭頸椎癌症治療藥市場預測

  • 市場規模與預測
    • 各銷售額
  • 市場佔有率與預測
    • 各診斷方法
    • 各治療類型
    • 各疾病適應症
    • 各給藥途徑
    • 各治療等級
    • 各終端用戶
    • 各國
  • 亞太地區:各國分析
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
    • 新加坡

第10章 南美的頭頸椎癌症治療藥市場預測

  • 市場規模與預測
    • 各銷售額
  • 市場佔有率與預測
    • 各診斷方法
    • 各治療類型
    • 各疾病適應症
    • 各給藥途徑
    • 各治療等級
    • 各終端用戶
    • 各國
  • 南美:各國分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第11章 中東及非洲的頭頸椎癌症治療藥市場預測

  • 市場規模與預測
    • 各銷售額
  • 市場佔有率與預測
    • 各診斷方法
    • 各治療類型
    • 各疾病適應症
    • 各給藥途徑
    • 各治療等級
    • 各終端用戶
    • 各國
  • 中東、非洲:各國分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第12章 臨床試驗分析

第13章 市場動態

  • 成長要素
  • 課題

第14章 市場趨勢

第15章 競爭情形

  • 競爭預測
  • 企業簡介(主要企業)
    • AstraZeneca Plc.
    • Astellas Pharma Inc.
    • AB Science SA
    • Bristol-Myers Squibb Company
    • Boston Biomedical, Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.(Genentech, Inc.,)
    • Fresenius Medical Care AG & Co. KGaA
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Limited
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Sanofi S.A.
    • Bayer AG
    • AbbVie Inc.

第16章 策略性建議

第17章 關於本公司&免責聲明

目錄
Product Code: 5056

Global head and neck cancer therapeutics market is expected to witness significant CAGR of 7.71% during the forecast period to reach USD2934.26 million owing to rising patient pool suffering from head and neck cancer around the world. Cancer awareness programs being organized by governments and various private organizations are leading to growing awareness and early cancer diagnosis among the population. This is acting as major growth driver for the global head and neck cancer therapeutics market. Moreover, increasing geriatric population which is more vulnerable to cancer is also acting as a key growth driver for this market.

According to the Union for International Cancer Control (UICC), around 550,000 people are diagnosed with head and neck cancer every year and out of these, around 300,000 patients die. With improved healthcare service and beneficial healthcare reforms, there is a spike in demand for head and neck cancer therapeutics around the globe. Additionally, extensive R&D activities to develop ideal therapeutics are expected to augment the market growth in the coming years.

Global head and neck cancer therapeutics market can be segmented based on diagnostic methods, treatment type, disease indication, route of administration, therapeutic class, end user and region. Based on therapeutic class, the market can be segmented into PD inhibitors, microtubule inhibitors and EGFR inhibitors. Among them, PD inhibitor drug class is expected to witness healthy CAGR through 2026 owing to new product launches and their increasing application in the treatment of head and neck cancer.

Regionally, North America contributed to the largest market share in global head and neck cancer therapeutics market in 2020 and is further expected to dominate the market through 2026, which can be attributed to high prevalence HPV-induced cancers in countries like United States, Canada, etc. However, Asia Pacific is anticipated to register the fastest growth during the forecast period as the region is witnessing increasing cases of head and neck cancer due to prevalence of risk factors like increase in cigarette smoking and usage of tobacco.

Major companies operating in the global head and neck cancer therapeutics market include AstraZeneca Plc., Astellas Pharma Inc., AB Science SA, Bristol-Myers Squibb Company, Boston Biomedical, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Fresenius Medical Care AG & Co. KGaA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Bayer AG and AbbVie Inc., among others. The market players are focusing on R&D activities and new drug launches to strengthen their position in global market.

Years considered for this report:

Historical Years: 2016-2019

Base Year: 2020

Estimated Year: 2021

Forecast Period: 2022-2026

Objective of the Study:

  • To analyze the historical growth in the market size of global head and neck cancer therapeutics market from 2016 to 2020.
  • To estimate and forecast the market size of the global head and neck cancer therapeutics market from 2021 to 2026 and growth rate until 2026.
  • To forecast global head and neck cancer therapeutics market based on diagnostic methods, treatment type, disease indication, route of administration, therapeutic class, end user, company and regional distribution.
  • To identify drivers and challenges for global head and neck cancer therapeutics market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in global head and neck cancer therapeutics market.
  • To identify and analyze the profile of leading players operating in the global head and neck cancer therapeutics market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of head and neck cancer therapeutics companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies which could not be identified due to the limitations of secondary research.

TechSci Research calculated global head and neck cancer therapeutics market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analysing historical data of these therapy types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by TechSci Research.

Key Target Audience:

  • Head and neck cancer therapeutics drug manufacturers, companies/partners and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to head and neck cancer therapeutics
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as head and neck cancer therapeutics drug manufacturers, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global head and neck cancer therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Head and Neck Cancer Therapeutics Market, By Diagnostic Methods:

Biopsy

Imaging

Endoscopy

Others

  • Global Head and Neck Cancer Therapeutics Market, By Treatment Type:

Surgery

Radiation Therapy

Chemotherapy

Immunotherapy

Targeted Therapy

  • Global Head and Neck Cancer Therapeutics Market, By Disease Indication:

Lip and Oral Cavity Cancer

Laryngeal Cancer

Oropharyngeal Cancer

Salivary Gland Cancer

Nasopharyngeal Cancer

Hypopharyngeal Cancer

  • Global Head and Neck Cancer Therapeutics Market, By Route of Administration:

Injectable

Oral

  • Global Head and Neck Cancer Therapeutics Market, By Therapeutic Class:

PD Inhibitors

EGFR Inhibitors

Microtubule Inhibitors

  • Global Head and Neck Cancer Therapeutics Market, By End User:

Hospitals

Specialty Clinics

Ambulatory Surgical Centres

Others

  • Global Head and Neck Cancer Therapeutics Market, By Region:

North America

  • United States
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy

Asia-Pacific

  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Singapore

South America

  • Brazil
  • Argentina
  • Colombia

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global head and neck cancer therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Head and Neck Cancer Therapeutics Market

4. Executive Summary

5. Voice of Customer

  • 5.1. Brand Awareness & Brand Recall
  • 5.2. Factors Influencing Purchase Decision
  • 5.3. Unmet Needs & Challenges

6. Global Head and Neck Cancer Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others)
    • 6.2.2. By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy)
    • 6.2.3. By Disease Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer)
    • 6.2.4. By Route of Administration (Injectable, Oral)
    • 6.2.5. By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors)
    • 6.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 6.2.7. By Company (2020)
    • 6.2.8. By Region
  • 6.3. Product Market Map

7. North America Head and Neck Cancer Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Diagnostic Methods
    • 7.2.2. By Treatment Type
    • 7.2.3. By Disease Indication
    • 7.2.4. By Route of Administration
    • 7.2.5. By Therapeutic Class
    • 7.2.6. By End User
    • 7.2.7. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Head and Neck Cancer Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Diagnostic Methods
        • 7.3.1.2.2. By Treatment Type
        • 7.3.1.2.3. By Disease Indication
        • 7.3.1.2.4. By Route of Administration
        • 7.3.1.2.5. By Therapeutic Class
        • 7.3.1.2.6. By End User
    • 7.3.2. Canada Head and Neck Cancer Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Diagnostic Methods
        • 7.3.2.2.2. By Treatment Type
        • 7.3.2.2.3. By Disease Indication
        • 7.3.2.2.4. By Route of Administration
        • 7.3.2.2.5. By Therapeutic Class
        • 7.3.2.2.6. By End User
    • 7.3.3. Mexico Head and Neck Cancer Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Diagnostic Methods
        • 7.3.3.2.2. By Treatment Type
        • 7.3.3.2.3. By Disease Indication
        • 7.3.3.2.4. By Route of Administration
        • 7.3.3.2.5. By Therapeutic Class
        • 7.3.3.2.6. By End User

8. Europe Head and Neck Cancer Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Diagnostic Methods
    • 8.2.2. By Treatment Type
    • 8.2.3. By Disease Indication
    • 8.2.4. By Route of Administration
    • 8.2.5. By Therapeutic Class
    • 8.2.6. By End User
    • 8.2.7. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. Germany Head and Neck Cancer Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Diagnostic Methods
        • 8.3.1.2.2. By Treatment Type
        • 8.3.1.2.3. By Disease Indication
        • 8.3.1.2.4. By Route of Administration
        • 8.3.1.2.5. By Therapeutic Class
        • 8.3.1.2.6. By End User
    • 8.3.2. France Head and Neck Cancer Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Diagnostic Methods
        • 8.3.2.2.2. By Treatment Type
        • 8.3.2.2.3. By Disease Indication
        • 8.3.2.2.4. By Route of Administration
        • 8.3.2.2.5. By Therapeutic Class
        • 8.3.2.2.6. By End User
    • 8.3.3. United Kingdom Head and Neck Cancer Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Diagnostic Methods
        • 8.3.3.2.2. By Treatment Type
        • 8.3.3.2.3. By Disease Indication
        • 8.3.3.2.4. By Route of Administration
        • 8.3.3.2.5. By Therapeutic Class
        • 8.3.3.2.6. By End User
    • 8.3.4. Spain Head and Neck Cancer Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Diagnostic Methods
        • 8.3.4.2.2. By Treatment Type
        • 8.3.4.2.3. By Disease Indication
        • 8.3.4.2.4. By Route of Administration
        • 8.3.4.2.5. By Therapeutic Class
        • 8.3.4.2.6. By End User
    • 8.3.5. Italy Head and Neck Cancer Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Diagnostic Methods
        • 8.3.5.2.2. By Treatment Type
        • 8.3.5.2.3. By Disease Indication
        • 8.3.5.2.4. By Route of Administration
        • 8.3.5.2.5. By Therapeutic Class
        • 8.3.5.2.6. By End User

9. Asia-Pacific Head and Neck Cancer Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Diagnostic Methods
    • 9.2.2. By Treatment Type
    • 9.2.3. By Disease Indication
    • 9.2.4. By Route of Administration
    • 9.2.5. By Therapeutic Class
    • 9.2.6. By End User
    • 9.2.7. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Head and Neck Cancer Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Diagnostic Methods
        • 9.3.1.2.2. By Treatment Type
        • 9.3.1.2.3. By Disease Indication
        • 9.3.1.2.4. By Route of Administration
        • 9.3.1.2.5. By Therapeutic Class
        • 9.3.1.2.6. By End User
    • 9.3.2. India Head and Neck Cancer Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Diagnostic Methods
        • 9.3.2.2.2. By Treatment Type
        • 9.3.2.2.3. By Disease Indication
        • 9.3.2.2.4. By Route of Administration
        • 9.3.2.2.5. By Therapeutic Class
        • 9.3.2.2.6. By End User
    • 9.3.3. Japan Head and Neck Cancer Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Diagnostic Methods
        • 9.3.3.2.2. By Treatment Type
        • 9.3.3.2.3. By Disease Indication
        • 9.3.3.2.4. By Route of Administration
        • 9.3.3.2.5. By Therapeutic Class
        • 9.3.3.2.6. By End User
    • 9.3.4. Australia Head and Neck Cancer Therapeutics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Diagnostic Methods
        • 9.3.4.2.2. By Treatment Type
        • 9.3.4.2.3. By Disease Indication
        • 9.3.4.2.4. By Route of Administration
        • 9.3.4.2.5. By Therapeutic Class
        • 9.3.4.2.6. By End User
    • 9.3.5. South Korea Head and Neck Cancer Therapeutics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Diagnostic Methods
        • 9.3.5.2.2. By Treatment Type
        • 9.3.5.2.3. By Disease Indication
        • 9.3.5.2.4. By Route of Administration
        • 9.3.5.2.5. By Therapeutic Class
        • 9.3.5.2.6. By End User
    • 9.3.6. Singapore Head and Neck Cancer Therapeutics Market Outlook
      • 9.3.6.1. Market Size & Forecast
        • 9.3.6.1.1. By Value
      • 9.3.6.2. Market Share & Forecast
        • 9.3.6.2.1. By Diagnostic Methods
        • 9.3.6.2.2. By Treatment Type
        • 9.3.6.2.3. By Disease Indication
        • 9.3.6.2.4. By Route of Administration
        • 9.3.6.2.5. By Therapeutic Class
        • 9.3.6.2.6. By End User

10. South America Head and Neck Cancer Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Diagnostic Methods
    • 10.2.2. By Treatment Type
    • 10.2.3. By Disease Indication
    • 10.2.4. By Route of Administration
    • 10.2.5. By Therapeutic Class
    • 10.2.6. By End User
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Head and Neck Cancer Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Diagnostic Methods
        • 10.3.1.2.2. By Treatment Type
        • 10.3.1.2.3. By Disease Indication
        • 10.3.1.2.4. By Route of Administration
        • 10.3.1.2.5. By Therapeutic Class
        • 10.3.1.2.6. By End User
    • 10.3.2. Argentina Head and Neck Cancer Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Diagnostic Methods
        • 10.3.2.2.2. By Treatment Type
        • 10.3.2.2.3. By Disease Indication
        • 10.3.2.2.4. By Route of Administration
        • 10.3.2.2.5. By Therapeutic Class
        • 10.3.2.2.6. By End User
    • 10.3.3. Colombia Head and Neck Cancer Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Diagnostic Methods
        • 10.3.3.2.2. By Treatment Type
        • 10.3.3.2.3. By Disease Indication
        • 10.3.3.2.4. By Route of Administration
        • 10.3.3.2.5. By Therapeutic Class
        • 10.3.3.2.6. By End User

11. Middle East and Africa Head and Neck Cancer Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Diagnostic Methods
    • 11.2.2. By Treatment Type
    • 11.2.3. By Disease Indication
    • 11.2.4. By Route of Administration
    • 11.2.5. By Therapeutic Class
    • 11.2.6. By End User
    • 11.2.7. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Head and Neck Cancer Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Diagnostic Methods
        • 11.3.1.2.2. By Treatment Type
        • 11.3.1.2.3. By Disease Indication
        • 11.3.1.2.4. By Route of Administration
        • 11.3.1.2.5. By Therapeutic Class
        • 11.3.1.2.6. By End User
    • 11.3.2. Saudi Arabia Head and Neck Cancer Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Diagnostic Methods
        • 11.3.2.2.2. By Treatment Type
        • 11.3.2.2.3. By Disease Indication
        • 11.3.2.2.4. By Route of Administration
        • 11.3.2.2.5. By Therapeutic Class
        • 11.3.2.2.6. By End User
    • 11.3.3. UAE Head and Neck Cancer Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Diagnostic Methods
        • 11.3.3.2.2. By Treatment Type
        • 11.3.3.2.3. By Disease Indication
        • 11.3.3.2.4. By Route of Administration
        • 11.3.3.2.5. By Therapeutic Class
        • 11.3.3.2.6. By End User

12. Clinical Trial Analysis

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

15. Competitive Landscape

  • 15.1. Competition Outlook
  • 15.2. Players Profiled (Leading Companies)
    • 15.2.1. AstraZeneca Plc.
    • 15.2.2. Astellas Pharma Inc.
    • 15.2.3. AB Science SA
    • 15.2.4. Bristol-Myers Squibb Company
    • 15.2.5. Boston Biomedical, Inc.
    • 15.2.6. Eli Lilly and Company
    • 15.2.7. F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
    • 15.2.8. Fresenius Medical Care AG & Co. KGaA
    • 15.2.9. Sun Pharmaceutical Industries Ltd.
    • 15.2.10. Teva Pharmaceutical Industries Limited
    • 15.2.11. Merck & Co., Inc.
    • 15.2.12. Pfizer Inc.
    • 15.2.13. Sanofi S.A.
    • 15.2.14. Bayer AG
    • 15.2.15. AbbVie Inc.

16. Strategic Recommendations

17. About Us & Disclaimer

List of Figures

  • Figure 1: Global Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 2: Global Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 3: Global Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 4: Global Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 5: Global Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 6: Global Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 7: Global Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 8: Global Head and Neck Cancer Therapeutics Market, By Company, 2020
  • Figure 9: Global Head and Neck Cancer Therapeutics Market, By Region, 2016-2026F
  • Figure 10: Global Head and Neck Cancer Therapeutics Market, Market Map, By Value, 2016-2026F
  • Figure 11: North America Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 12: North America Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 13: North America Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 14: North America Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 15: North America Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 16: North America Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 17: North America Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 18: North America Head and Neck Cancer Therapeutics Market, By Country, By Value, 2016-2026F
  • Figure 19: United States Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 20: United States Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 21: United States Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 22: United States Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 23: United States Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 24: United States Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 25: United States Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 26: Canada Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 27: Canada Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 28: Canada Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 29: Canada Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 30: Canada Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 31: Canada Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 32: Canada Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 33: Mexico Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 34: Mexico Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 35: Mexico Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 36: Mexico Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 37: Mexico Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 38: Mexico Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 39: Mexico Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 40: Europe Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 41: Europe Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 42: Europe Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 43: Europe Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 44: Europe Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 45: Europe Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 46: Europe Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 47: Europe Head and Neck Cancer Therapeutics Market, By Country, By Value, 2016-2026F
  • Figure 48: Germany Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 49: Germany Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 50: Germany Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 51: Germany Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 52: Germany Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 53: Germany Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 54: Germany Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 55: France Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 56: France Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 57: France Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 58: France Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 59: France Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 60: France Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 61: France Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 62: United Kingdom Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 63: United Kingdom Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 64: United Kingdom Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 65: United Kingdom Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 66: United Kingdom Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 67: United Kingdom Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 68: United Kingdom Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 69: Spain Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 70: Spain Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 71: Spain Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 72: Spain Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 73: Spain Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 74: Spain Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 75: Spain Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 76: Italy Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 77: Italy Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 78: Italy Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 79: Italy Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 80: Italy Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 81: Italy Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 82: Italy Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 83: Asia-Pacific Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 84: Asia-Pacific Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 85: Asia-Pacific Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 86: Asia-Pacific Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 87: Asia-Pacific Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 88: Asia-Pacific Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 89: Asia-Pacific Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 90: Asia-Pacific Head and Neck Cancer Therapeutics Market, By Country, By Value, 2016-2026F
  • Figure 91: China Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 92: China Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 93: China Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 94: China Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 95: China Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 96: China Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 97: China Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 98: India Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 99: India Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 100: India Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 101: India Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 102: India Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 103: India Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 104: India Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 105: Japan Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 106: Japan Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 107: Japan Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 108: Japan Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 109: Japan Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 110: Japan Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 111: Japan Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 112: Australia Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 113: Australia Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 114: Australia Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 115: Australia Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 116: Australia Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 117: Australia Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 118: Australia Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 119: South Korea Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 120: South Korea Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 121: South Korea Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 122: South Korea Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 123: South Korea Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 124: South Korea Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 125: South Korea Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 126: Singapore Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 127: Singapore Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 128: Singapore Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 129: Singapore Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 130: Singapore Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 131: Singapore Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 132: Singapore Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 133: South America Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 134: South America Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 135: South America Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 136: South America Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 137: South America Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 138: South America Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 139: South America Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 140: South America Head and Neck Cancer Therapeutics Market, By Country, By Value, 2016-2026F
  • Figure 141: Brazil Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 142: Brazil Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 143: Brazil Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 144: Brazil Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 145: Brazil Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 146: Brazil Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 147: Brazil Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 148: Argentina Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 149: Argentina Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 150: Argentina Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 151: Argentina Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 152: Argentina Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 153: Argentina Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 154: Argentina Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 155: Colombia Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 156: Colombia Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 157: Colombia Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 158: Colombia Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 159: Colombia Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 160: Colombia Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 161: Colombia Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 162: Middle East and Africa Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 163: Middle East and Africa Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 164: Middle East and Africa Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 165: Middle East and Africa Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 166: Middle East and Africa Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 167: Middle East Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 168: Middle East Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 169: Middle East and Africa Head and Neck Cancer Therapeutics Market, By Country, By Value, 2016-2026F
  • Figure 170: South Africa Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 171: South Africa Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 172: South Africa Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 173: South Africa Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 174: South Africa Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 175: South Africa Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 176: South Africa Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 177: Saudi Arabia Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 178: Saudi Arabia Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 179: Saudi Arabia Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 180: Saudi Arabia Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 181: Saudi Arabia Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 182: Saudi Arabia Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 183: Saudi Arabia Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F
  • Figure 184: UAE Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2016-2026F
  • Figure 185: UAE Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2016-2026F
  • Figure 186: UAE Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2016-2026F
  • Figure 187: UAE Head and Neck Cancer Therapeutics Market Share, By Disease Indication, By Value, 2016-2026F
  • Figure 188: UAE Head and Neck Cancer Therapeutics Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 189: UAE Head and Neck Cancer Therapeutics Market Share, By Therapeutic Class, By Value, 2016-2026F
  • Figure 190: UAE Head and Neck Cancer Therapeutics Market Share, By End-User, By Value, 2016-2026F